Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LOXL2 | Q9Y4K0 | 11/20 | 0.70 |
| ▸ | ASIC3 | Q9UHC3 | 2/20 | 0.58 |
| ▸ | LOX | P28300 | 4/20 | 0.51 |
| ▸ | LOXL3 | P58215 | 1/20 | 0.50 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.47 |
| ▸ | CSNK2A1 | P68400 | 2/20 | 0.44 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.44 |
| ▸ | AURKA | O14965 | 1/20 | 0.44 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.44 |
| ▸ | PRKACA | P17612 | 1/20 | 0.44 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.44 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.43 |
| ▸ | HTR1A | P08908 | 1/20 | 0.43 |
| ▸ | HTR7 | P34969 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL352525 | 0.83 | LOXL2 (0.61) | LOXL2LOXLOXL3 | |
| SCHEMBL14303459 | 0.83 | LOXL2 (0.64) | LOXL2ASIC3LOXLOXL3IRAK4 | |
| SCHEMBL18049294 | 0.82 | LOXL2 (1.00) | LOXL2LOXLOXL3HSP90AA1 | |
| SCHEMBL18069362 | 0.82 | LOXL2 (0.76) | LOXL2LOX | |
| SCHEMBL28505430 | 0.81 | LOXL2 (0.58) | LOXL2ASIC3LOXLOXL3IRAK4 | |
| SCHEMBL18233498 | 0.81 | LOXL2 (0.62) | LOXL2LOXLOXL3TAAR1NOTUM | |
| SCHEMBL18049349 | 0.81 | LOXL2 (0.62) | LOXL2LOXLOXL3TAAR1IRAK4 | |
| SCHEMBL30485802 | 0.81 | LOXL2 (0.56) | LOXL2LOXLOXL3HSP90AA1 | |
| SCHEMBL7036361 | 0.81 | LOXL2 (0.56) | LOXL2LOXLOXL3HSP90AA1 | |
| SCHEMBL10434579 | 0.81 | ASIC3 (0.53) | LOXL2ASIC3AURKAHSP90AA1PRKACA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-104045683-A | Polypeptide fluorescence cyclization method based on metal iridium complex and cyclized polypeptide | SUZHOU INST NANO TECH & NANO B | 2014-09-17 | — | — | CN | claimed |
| CN-101750486-A | Method for labeling antibody by fluorophore generated by combination of iridium coordination compound and histidine | SUNA TECH INC | 2010-06-23 | — | — | CN | claimed |
| CN-107922400-B | Muscarinic M1 receptor positive allosteric modulators | 苏文生命科学有限公司 | 2021-05-11 | — | — | CN | disclosed |
| US-10308620-B2 | Muscarinic M1 receptor positive allosteric modulators | SUVEN LIFE SCIENCES LIMITED (IN) | 2019-06-04 | — | — | US | disclosed |
| US-20180155302-A1 | MUSCARINIC M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS | SUVEN LIFE SCIENCES LIMITED (IN) | 2018-06-07 | — | — | US | disclosed |
| EP-3303331-A1 | MUSCARINIC M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS | Suven Life Sciences Limited (IN) | 2018-04-11 | — | — | EP | disclosed |
| WO-2016198937-A1 | MUSCARINIC M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS | SUVEN LIFE SCIENCES LIMITED (IN) | 2016-12-15 | — | — | WO | disclosed |
| CN-104045683-A | Polypeptide fluorescence cyclization method based on metal iridium complex and cyclized polypeptide | SUZHOU INST NANO TECH & NANO B | 2014-09-17 | — | — | CN | disclosed |
| WO-2014065411-A1 | SULFONAMIDE DERIVATIVE AS HARMFUL-ORGANISM CONTROL AGENT FOR AGRICULTURAL/HORTICULTURAL USE | 株式会社エス・ディー・エス バイオテック (JP) | 2014-05-01 | — | — | WO | disclosed |
| US-20060287378-A1 | Novel pyrroles and imidazoles | WARNER-LAMBERT COMPANY LLC | 2006-12-21 | — | — | US | disclosed |
| US-20050239857-A1 | Novel imidazoles | BOLTON GARY L | 2005-10-27 | — | — | US | disclosed |
| CN-1180050-C | Metal ligand compound, luminous device and display device | ������������ʽ���� | 2004-12-15 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060287378-A1 | Novel pyrroles and imidazoles | PPIP5K2, PPIE, PPOX | LOXL2 4450/4885ASIC3 3481/4885LOX 3074/4885 |
| US-20050239857-A1 | Novel imidazoles | HMGCR, HMGB2, HMGB3 | LOXL2 1042/4885ASIC3 4850/4885LOX 466/4885 |
| US-10308620-B2 | Muscarinic M1 receptor positive allosteric modulators | CHRM1, CHRM2, CHRM3 | LOXL2 4725/4885ASIC3 801/4885LOX 4619/4885 |
| US-20180155302-A1 | MUSCARINIC M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS | CHRM1, CHRM2, CHRM3 | LOXL2 4725/4885ASIC3 801/4885LOX 4619/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.